<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065623</url>
  </required_header>
  <id_info>
    <org_study_id>12672</org_study_id>
    <secondary_id>2009-015085-58</secondary_id>
    <nct_id>NCT01065623</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open Label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY79-4620 Administered as an Intravenous Infusion Once Every 2 Weeks in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study to determine safety, tolerability, to measure how the drug is metabolized by&#xD;
      the body and to determine the maximum tolerated dose of BAY79-4620 given every 2 weeks to&#xD;
      patients with advanced solid tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to safety reasons&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event reporting</measure>
    <time_frame>Approximately 3 years after initiation of the trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics profile of BAY79-4620</measure>
    <time_frame>End of cycle 2 (14 days per cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers evaluation</measure>
    <time_frame>Approximately 3 years after initiation of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response evaluation</measure>
    <time_frame>Approximately 3 years after initiation of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity evaluation</measure>
    <time_frame>Approximately 3 years after initiation of the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY79-4620</intervention_name>
    <description>1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The informed consent must be signed before any study specific tests or procedures are&#xD;
             done&#xD;
&#xD;
          -  Male or female patients aged &gt;18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Patients with advanced, histologically or cytologically confirmed solid tumors,&#xD;
             refractory to any standard therapy, have no standard therapy available, or patients&#xD;
             must have actively refused any treatment which would be regarded standard, and/or if&#xD;
             in the judgment of the investigator or his designated associate(s), experimental&#xD;
             treatment is clinically and ethically acceptable&#xD;
&#xD;
          -  Radiographically or clinically evaluable tumor&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal functions as assessed by the following&#xD;
             laboratory requirements to be conducted within 14 days prior to start of first dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiac disease: congestive heart failure (CHF) &gt; NYHA Class II; myocardial&#xD;
             infarction within 3 months prior to study entry; new onset angina within 3 months or&#xD;
             unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta&#xD;
             blockers or digoxin are permitted)&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure &gt;160 mmHg and/or&#xD;
             diastolic blood pressure &gt;95 mmHg, despite optimal medical management&#xD;
&#xD;
          -  Symptomatic metastatic brain or meningeal tumors unless the patient is &gt;6 months from&#xD;
             definitive therapy, has no evidence of tumor growth on an imaging study within 2 weeks&#xD;
             prior to study entry, and is clinically stable with respect to the tumor at the time&#xD;
             of study entry.&#xD;
&#xD;
          -  Patients with severe renal impairment or on dialysis&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection or patients with an active&#xD;
             hepatitis B or C infection necessitating treatment. Patients with chronic hepatitis B&#xD;
             or C are eligible&#xD;
&#xD;
          -  Active clinically serious infections of Common Terminology Criteria for Adverse Events&#xD;
             Version 3 (CTCAE v3.0) &gt; Grade 2&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Major surgery, open biopsy, or significant trauma within 4 weeks prior to the first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Anticancer chemotherapy, experimental cancer therapy, or immunotherapy within 2 weeks&#xD;
             of start of first dose&#xD;
&#xD;
          -  Radiotherapy to the target lesions within 3 weeks prior to Cycle 1 Day 1 (first dose&#xD;
             of study drug). Palliative radiotherapy will be allowed as described in the study&#xD;
             protocol. Radiotherapy to the target lesions during study will be regarded as&#xD;
             progressive disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Immunoconjugate</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

